BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Wester

BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.

Abstract - Cancer predisposition: I say genetics, you say genomics, but are we there yet? -- Cancer Prevention Research

"A few examples include Lynch syndrome, hereditary breast-ovarian cancer syndrome and Cowden syndrome."

HTML Full Text - Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours

(included ovarian cancer patients in study)

Use of CT Scans Linked to Cancer Risk, Studies Say | netReturns | e-Newsletter

"There is considerable disagreement in the scientific community about the validity of these models," notes Rosaleen Parsons, M.D., chair of the department of diagnostic imaging at Fox Chase Cancer Center. "And some scientists believe the radiation dose from these CT scans may not lead to any increased risk of cancer."

In the second study, conducted at the University of California-San Francisco, researchers compared CT scan use at four San Francisco Bay area facilities. They found that the amount of radiation from a CT scan may be up to four times greater than estimated in previous studies. In addition, they noted significant differences among different institutions and, in some instances, within the same institution, when looking at the radiation dose associated with CT scans.

Learn.Genetics™ - a great site - easy to use & interactive/numerous sections of interest for all

media article: Plant-based flavonoid may cut ovarian cancer risk (Apigenin)

language issues: borderline - significant ??

"women reporting the highest apigenin intake had a "borderline significant decrease" in ovarian cancer risk"

Now's the time to find biomarkers on purpose -- Annals of Oncology

"Studies need to be conducted to determine the optimal design for using genome-wide profiling to identify putative biomarkers of drug response. To date, most biomarkers of drug response identified through genome-wide profiling have occurred through retrospective analysis of available tissue. To really progress this field, realistic planning for biomarker discovery and validation in clinical trials needs to be conducted. We, as clinical scientists, need to progress from only using convenient clinical cohorts to identify biomarkers to actually planning and following through with prospective clinical trials whose aims are to discover and/or validate putative biomarkers of drug response. To initiate a study without a realistic plan for discovery and validation reflects a lack of serious desire to find robust clinical predictors.^.... Until this becomes more commonplace, the genomic revolution will be focused on manuscript generation and investigator career development, leaving the benefit to patients nothing more than an unrealized dream."

Jan 26, 2010 NCI: Helping Breast Cancer Gene Mutation Carriers Weigh Prevention Choices

Note: charts

Jan 5th, 2010 Q&A: Understanding and Managing Lynch Syndrome - Cancerwise | Cancer blog from M. D. Anderson Cancer Center

Basic overview